-
POPULATION HEALTH IMPACTS ASSOCIATED WITH NEW INDICATIONS: A CASE STUDY OF SGLT2-INHIBITORS
Feb 25, 2026, 14:42 PM -
A REVIEW ON THE APPLICATION OF PATIENT-REPORTED OUTCOMES IN THE LABELING OF NEW ONCOLOGY DRUGS
Feb 25, 2026, 14:42 PM -
REAL-WORLD FRONT-LINE USE OF ENFORTUMAB VEDOTIN - PEMBROLIZUMAB (EV+P) AFTER ADJUVANT NIVOLUMAB IN ADVANCED UROTHELIAL CANCER(AUC)
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF EXTENDED-RELEASE NALTREXONE WITH MOBILE MEDICAL TREATMENT VERSUS STANDARD DELIVERY FOLLOWING INCARCERATION
Feb 25, 2026, 14:42 PM -
DEVELOPMENT AND VALIDATION OF AN AI-POWERED CLINICAL PHARMACIST ASSISTANT FOR PREDICTING ADVERSE DRUG REACTIONS IN INDIAN HOSPITALS
Feb 25, 2026, 14:42 PM -
EXPLORING PREFERENCES FOR LYME DISEASE VACCINES IN THE UNITED STATES: A LATENT CLASS APPROACH
Feb 25, 2026, 14:42 PM -
HEREDITARY ANGIOEDEMA IN MEXICO: ESTIMATING THE ECONOMIC BURDEN AND RESOURCE UTILIZATION IN PUBLIC HEALTHCARE
Feb 25, 2026, 14:42 PM -
IS SUICIDAL IDEATION RISK ASSOCIATED WITH PHARMACOTHERAPY IN ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)? A REAL-WORLD STUDY
Feb 25, 2026, 14:42 PM -
TEST-RETEST RELIABILITY OF CASE 1 BEST-WORST SCALING: EVIDENCE FROM RELATIVE ATTRIBUTE IMPORTANCE OF PREFERENCES FOR AI USE IN HEALTHCARE
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF INDIVIDUALISED PHYSIOTHERAPY USING THE STOPS APPROACH FOR CHRONIC LOW BACK PAIN IN BANGLADESH
Feb 25, 2026, 14:42 PM -
ORPHAN CELL AND GENE THERAPY APPROVALS IN THE US AND EUROPE: A COMPARATIVE ANALYSIS
Feb 25, 2026, 14:42 PM -
EFFICACY AND SAFETY OF ACUPOINT CATGUT EMBEDDING FOR KNEE OSTEOARTHRITIS: A-PRISMA COMPLIANT SYSTEMATIC REVIEW AND META-ANALYSIS
Feb 25, 2026, 14:42 PM -
HEALTHCARE COST, RESOURCE USE, AND ECONOMIC MODELS OF CISPLATIN-INELIGIBLE MUSCLE-INVASIVE BLADDER CANCER PATIENTS (MIBC)
Feb 25, 2026, 14:42 PM -
BUDGET IMPACT OF INTRODUCING TAPINAROF, A NEW ARYL HYDROCARBON RECEPTOR AGONIST, FOR THE TREATMENT OF ATOPIC DERMATITIS IN ADULT AND PEDIATRIC PATIENTS, FROM A U.S. MEDICAID PLAN PERSPECTIVE
Feb 25, 2026, 14:42 PM -
A COST OUTCOMES ANALYSIS OF APIXABAN VERSUS RIVAROXABAN FOR THE TREATMENT OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE UNITED STATES
Feb 25, 2026, 14:42 PM -
SUCCESSFUL USES OF REAL-WORLD EVIDENCE IN FDA LABEL UPDATES: A DESCRIPTIVE ANALYSIS OF REGULATORY TRENDS
Feb 25, 2026, 14:42 PM -
COST-EFFECTIVENESS OF SUBCUTANEOUS MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN FOR UNITED STATES (US) PATIENTS WITH AUTOLOGOUS STEM CELL TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
Feb 25, 2026, 14:42 PM -
COMPARING AN EXPERT-IN-THE-LOOP AI WORKFLOW WITH MANUAL SYSTEMATIC LITERATURE REVIEW: IMPLICATIONS FOR EFFICIENCY AND EVIDENCE QUALITY IN HEOR
Feb 25, 2026, 14:42 PM -
COMPARATIVE CARDIOVASCULAR RISK IN U.S. POSTMENOPAUSAL WOMEN STARTING ROMOSOZUMAB VS DENOSUMAB: A HIGH-DIMENSIONAL INVERSE PROBABILITY OF SELECTION WEIGHTING ANALYSIS FOR MISSING CARDIOVASCULAR RISK FACTORS
Feb 25, 2026, 14:42 PM -
REAL-WORLD EVIDENCE TO SUPPORT HEALTH TECHNOLOGY ASSESSMENT AND PAYER DECISION MAKING: A REVIEW OF POLICY AND GUIDANCE ACROSS EUROPE, CANADA, AND THE UNITED STATES
Feb 25, 2026, 14:42 PM
